Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoCaCRT: Cadonilimab + Chemoradiotherapy in Rectal Cancer
NCT05792735Phase 2Completed
- Sponsor
- Shenzhen People's Hospital
- Start
- Apr 2023
- Primary completion
- Oct 2024
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cadonilimab in rectal cancer, sponsored by Shenzhen People's Hospital. Started Apr 2023; status: completed.
02
Drugs
cadonilimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05792735.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05792735.